Drugs / CSL689
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02470871 | Jul 2015 → Jul 2016 | congenital factor VII deficiency | CSL Behring | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02484638 | Jul 2015 → Mar 2018 | hemophilia A, hemophilia B | CSL Behring | Terminated | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2013-07-03 | CSL Behring | CSL Behring Presents Phase I Results From Study of Recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP) in Healthy Volunteers csl.com ↗ |
| 2012-03-29 | CSL Behring | CSL Behring Commences Phase I study with rVIIa-FP, a Novel Therapy to Treat People With Hemophilia A and Hemophilia B Who Have Inhibitors csl.com ↗ |
| 2012-02-16 | CSL Behring | CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors csl.com ↗ |
| 2011-05-31 | CSL Behring | CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment csl.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSL689 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02470871 ↗ |
| Known as | rVIIa-FP | “Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a...” NCT02470871 ↗1“The purpose of this study is to investigate the pharmacokinetics (PK), efficacy, and safety of rVIIa-FP (CSL689).” NCT02484638 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP)” NCT02470871 ↗ |
| Route | Other | “CSL689 injection” NCT02470871 ↗ |